Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.

Mericq V, Lammoglia JJ, Unanue N, Villaroel C, Hernández MI, Avila A, Iñiguez G, Klein KO

Clinical endocrinology19 Mar 2009Cited by 21 (Europe PMC)

PMID19302581DOI10.1111/j.1365-2265.2009.03584.xPepBankPUB-19302581

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In girls with CPP, basal LH decreased significantly from baseline during months 3 to 12 in all leuprolide groups.
In plain wordsIn girls with CPP, basal LH decreased from baseline in all leuprolide groups.
Peptide
Leuprolide
Outcome
DecreaseBasal LH
Study
n = 14
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg/month, 11.25 or 22.5 mg every 3 months · 12 monthsAs given in this study (human).
Measurements
P
0.001
change from baseline, all groups
Source sentences
Summary
Basal and LHRH stimulated LH levels decreased significantly between baseline and from 3 up to 12 months of therapy in all groups (P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258101
02HumanNon-randomized trialEfficacy outcome
In girls with CPP, stimulated LH decreased significantly from baseline during months 3 to 12 in all leuprolide groups.
In plain wordsIn girls with CPP, stimulated LH decreased from baseline in all leuprolide groups.
Peptide
Leuprolide
Outcome
DecreaseLHRH-stimulated LH
Study
n = 14
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg/month, 11.25 or 22.5 mg every 3 months · 12 monthsAs given in this study (human).
Measurements
P
0.001
change from baseline, all groups
Source sentences
Summary
Basal and LHRH stimulated LH levels decreased significantly between baseline and from 3 up to 12 months of therapy in all groups (P = 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258102
03HumanNon-randomized trialEfficacy outcome
In girls with CPP, all patients had LH suppressed below 2 IU/l by 12 months of leuprolide treatment.
In plain wordsIn girls with CPP, all patients met the LH suppression criterion by 12 months.
Peptide
Leuprolide
Outcome
Not applicableLH suppression at 12 months
Study
n = 14
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg/month, 11.25 or 22.5 mg every 3 months · 12 monthsAs given in this study (human).
Measurements
Response
100%
12 months
Source sentences
Summary
By 12 months, 100% of patients had LH suppressed to <2 IU/l.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258106
04HumanNon-randomized trialEfficacy outcome
In girls with CPP, 80% met the stimulated LH criterion below 2 IU/l at 6 months with monthly 7.5 mg leuprolide.
In plain wordsIn girls with CPP, 80% met the LH suppression criterion at 6 months with monthly 7.5 mg leuprolide.
Peptide
Leuprolide
Outcome
Not applicableLH suppression at 6 months
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
7.5 mg monthly · 6 monthsAs given in this study (human).
Measurements
Response
80%
7.5 mg
Source sentences
Summary
GnRH stimulated LH peak <2 IU/l, the main efficacy criterion was met in 80, 75 and 100% of the children at 6 months in the 7.5, 11.25, 22.5 mg doses respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258103
05HumanNon-randomized trialEfficacy outcome
In girls with CPP, 75% met the stimulated LH criterion below 2 IU/l at 6 months with 11.25 mg leuprolide.
In plain wordsIn girls with CPP, 75% met the LH suppression criterion at 6 months with 11.25 mg leuprolide.
Peptide
Leuprolide
Outcome
Not applicableLH suppression at 6 months
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
Response
75%
11.25 mg
Source sentences
Summary
GnRH stimulated LH peak <2 IU/l, the main efficacy criterion was met in 80, 75 and 100% of the children at 6 months in the 7.5, 11.25, 22.5 mg doses respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258104
06HumanNon-randomized trialEfficacy outcome
In girls with CPP, 100% met the stimulated LH criterion below 2 IU/l at 6 months with 22.5 mg leuprolide.
In plain wordsIn girls with CPP, 100% met the LH suppression criterion at 6 months with 22.5 mg leuprolide.
Peptide
Leuprolide
Outcome
Not applicableLH suppression at 6 months
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
22.5 mg every 3 months · 6 monthsAs given in this study (human).
Measurements
Response
100%
22.5 mg
Source sentences
Summary
GnRH stimulated LH peak <2 IU/l, the main efficacy criterion was met in 80, 75 and 100% of the children at 6 months in the 7.5, 11.25, 22.5 mg doses respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In an open 12-month protocol, we evaluated LA 7.5 mg/month, 11.25 and 22.5 every 3 months.
Summary · context
Fourteen girls with CPP and weights over 30 kg.
Report a problemFND-1930258105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.